![Tom Willis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Rebecca Critchley-Thorne | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | 16 años |
Mike Hoerres | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | - |
Noel Thomas Doheny | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | - |
Ephraim F. Gildor | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | - |
Gregg Fergus | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | - |
John Inadomi | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | - |
Nicholas Shaheen | M | - |
Cernostics, Inc.
![]() Cernostics, Inc. Medical SpecialtiesHealth Technology Cernostics, Inc. develops and commercializes cancer diagnostic tests. Its technology is based on a systems approach to evaluating tissues via anatomic pathology and simultaneously evaluates immune, stromal, stem cell and tumor biomarkers on a single slide while preserving tissue structure. The company was founded in 2008 by Michel Nederlof and Rebecca Critchley-Thorne and is headquartered in Pittsburgh, PA. | - |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 7 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Tom Willis
- Red Personal